Shilpa Medicare Ltd. reported a sharp jump in profitability for the quarter ended June 30, 2025, with consolidated net profit surging to ₹46.89 crore, up over threefold from ₹14.06 crore in the year-ago period.
Revenue from operations grew 9.9% year-on-year to ₹321.45 crore compared to ₹292.51 crore in Q1 FY25. Sequentially, revenue dipped 3% from ₹338.04 crore in Q4 FY25.
The company’s total income for the quarter stood at ₹327.83 crore, while total expenses rose to ₹277.52 crore from ₹269.88 crore a year earlier. Shilpa Medicare said it continues to focus on strengthening its specialty pharmaceuticals and oncology portfolio, alongside expanding its global footprint in regulated markets.
Disclaimer: The information provided is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and investors should consult with their financial advisor before making investment decisions.
